[New antiretroviral medications in therapy of HIV infections].
Therapeutic options continue to expand with the development of new drugs and new strategies for using them. This report describes progress in laboratory and clinical trials of new inhibitors of reverse transcriptase and viral protease, turning special attention on their efficacy for therapy of patient with drug resistant viruses for current therapies. The second group is a new class of anti-HIV drugs called "fusion inhibitors" or "viral entry inhibitors" The fusion inhibitors halt HIV at a unique point in the virus life cycle blocking attachment of virus to the membrane of target cells. All of the described drugs are not potent enough to eradicate the virus. Diminished toxicity of proposed new antiretroviral substances, more tolerable regimens easier for patients and efficacy against resistant viruses to currently used drugs are giving hope for further prolongation of life of HIV infected patients.